See you at the 43rd Annual J.P. Morgan Healthcare Conference! Our CEO, James Porter present on January 14, 2025, at 9:00 AM PST. 📅 A recording of the presentation will be available on the conference website for 30 days. #JPMorgan #JPM25 #Oncology
Nuvalent, Inc.
Biotechnology Research
Cambridge, Massachusetts 6,259 followers
#PreciselyTargetedTherapies for patients with cancer
About us
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
- Website
-
https://www.nuvalent.com/
External link for Nuvalent, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
One Broadway 14th Floor
Cambridge, Massachusetts 02142, US
Employees at Nuvalent, Inc.
Updates
-
Meet our newest additions to the #NuCrew. Welcome Sammy, Melissa, Megan, and Ren!
-
-
Join us in welcoming Grant Bogle to our board of directors! We welcome his collaboration and insights as we work toward our goal of a first potential approval in 2026 from our pipeline of precisely targeted therapies for patients with cancer. Learn more: https://bit.ly/3ZKAT9J #Biotech #BusinessDevelopment #Oncology
-
-
📣 The #NuCrew is hiring! We are on the lookout for an Associate Director, Formulation Sciences! Learn more about this role and other new opportunities here: https://lnkd.in/eXrTn9xN #NuTalent #hiring #biotech
-
-
This Lung Cancer Awareness Month, we hope to bring awareness to cancer research and the importance of understanding patient perspectives. Thank you to all those who have dedicated your time and shared your unique experiences with us as we strive to develop new treatment options for those impacted by #lungcancer. #LCAM
-
-
Nuvalent CEO James Porter and CFO Alex Balcom, MBA, CPA are back in NYC next month for Piper Sandler’s 36th Annual Healthcare Conference. A recording of the webcast will be available on our website for 30 days. https://lnkd.in/ezSFCWSZ $NUVL #biotech #oncology
-
-
The #NuCrew is filled with passionate and innovative scientists! In September, Scot Mente, Director of Computational Chemistry, shared insights on molecular dynamics simulations at #EuroQSAR 2024.
-
-
Meet the newest members of the #NuCrew: Mei, Brett, Jason, and Steve! We are grateful to have you on board!
-
-
Join Nuvalent CEO James Porter CFO Alex Balcom, MBA, CPA this month at Guggenheim Partners's Inaugural Healthcare Innovation Conference in Boston and the Stifel Financial Corp. 2024 Healthcare Conference in NYC. Recordings of the webcasts will be available on our website for 30 days. https://lnkd.in/dkTtC2ux $NUVL #biotech #oncology
-
-
$NUVL: Q3 2024 Highlights ✅ Achievement of all anticipated 2024 milestones outlined in OnTarget 2026 operating plan 🔬 Announced planned initiation of the ALKAZAR Phase 3 trial of NVL-655 in 1H 2025 🤝 Welcomed Alice Shaw MD, PhD to our Scientific Advisory Board ⬆ Upsized public offering expected to extend operating runway into 2028 Check out more on these business updates and our full third quarter financial results: https://lnkd.in/erA4-5mc
-